Literature DB >> 22937988

Limitations of the risk factor based approach in early neonatal sepsis evaluations.

Orna Flidel-Rimon1, Sophie Galstyan, Ada Juster-Reicher, Ilya Rozin, Eric S Shinwell.   

Abstract

AIM: Guidelines for detection of early neonatal sepsis employ a risk factor approach combined with laboratory parameters. In an era of increasing intrapartum antibiotic prophylaxis (IAP), we re-assessed the approach as a whole and each of the risk factors individually.
METHOD: This retrospective study included infants with risk factors for sepsis or those treated with antibiotics or who had documented early sepsis. Safety of the protocol was assessed by the number of cases of either missed or partially treated late sepsis or meningitis and the sepsis-related mortality rate. Predictive value of each clinical and laboratory factor was calculated.
RESULTS: Of the 22,215 neonates, 2096 were assessed. IAP among infants with risk factors rose from 68% in 2005 to 78% in 2008 (p = 0.001). A total of 1662 asymptomatic infants had risk factors, 635 received antibiotics and one (0.06%) had sepsis. A total of 434 symptomatic infants were treated with antibiotics and of these 234 had risk factors and 20 (4.6%) had sepsis. No cases of partially treated or missed sepsis were detected. Poor predictive value was found for all risk factors except prematurity and leukopenia.
CONCLUSION: The risk factor based approach in asymptomatic infants cannot be justified. In-hospital observation of asymptomatic infants for 2-3 days with antibiotic treatment being reserved only for symptomatic infants may be a reasonable alternative.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 22937988     DOI: 10.1111/apa.12013

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Strategies for preventing group B streptococcal infections in newborns: a nation-wide survey of Italian policies.

Authors:  Chryssoula Tzialla; Alberto Berardi; Claudio Farina; Pierangelo Clerici; Alessandro Borghesi; Elsa Viora; Paolo Scollo; Mauro Stronati
Journal:  Ital J Pediatr       Date:  2017-11-02       Impact factor: 2.638

Review 2.  Reappraisal of guidelines for management of neonates with suspected early-onset sepsis.

Authors:  William E Benitz; James L Wynn; Richard A Polin
Journal:  J Pediatr       Date:  2015-01-29       Impact factor: 4.406

3.  Anti-microbial stewardship: antibiotic use in well-appearing term neonates born to mothers with chorioamnionitis.

Authors:  N Money; J Newman; S Demissie; P Roth; J Blau
Journal:  J Perinatol       Date:  2017-10-05       Impact factor: 2.521

4.  Incidence of early-onset sepsis in infants born to women with clinical chorioamnionitis.

Authors:  Tara M Randis; Madeline Murguia Rice; Leslie Myatt; Alan T N Tita; Kenneth J Leveno; Uma M Reddy; Michael W Varner; John M Thorp; Brian M Mercer; Mara J Dinsmoor; Susan M Ramin; Marshall W Carpenter; Philip Samuels; Anthony Sciscione; Jorge E Tolosa; George Saade; Yoram Sorokin
Journal:  J Perinat Med       Date:  2018-10-25       Impact factor: 2.716

5.  Serial physical examinations, a simple and reliable tool for managing neonates at risk for early-onset sepsis.

Authors:  Alberto Berardi; Anna Maria Buffagni; Cecilia Rossi; Eleonora Vaccina; Chiara Cattelani; Lucia Gambini; Federica Baccilieri; Francesca Varioli; Fabrizio Ferrari
Journal:  World J Clin Pediatr       Date:  2016-11-08

6.  Group B Streptococcus early-onset disease and observation of well-appearing newborns.

Authors:  Alberto Berardi; Caterina Spada; Maria Letizia Bacchi Reggiani; Roberta Creti; Lorenza Baroni; Maria Grazia Capretti; Matilde Ciccia; Valentina Fiorini; Lucia Gambini; Giancarlo Gargano; Irene Papa; Giancarlo Piccinini; Vittoria Rizzo; Fabrizio Sandri; Laura Lucaccioni
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

7.  Effect of targeted vs standard fortification of breast milk on growth and development of preterm infants (≤ 32 weeks): study protocol for a randomized controlled trial.

Authors:  Joanna Seliga-Siwecka; Anna Chmielewska; Katarzyna Jasińska
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.